Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, PA 19104, USA.
Liver Transpl. 2013 Jun;19(6):619-26. doi: 10.1002/lt.23648.
Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are both associated with chronic kidney disease (CKD), a major complication after orthotopic liver transplantation (OLT). The aim of this study was to assess predictors of post-OLT CKD in HIV/HCV-coinfected recipients versus HIV-infected recipients without HCV (HIV/non-HCV recipients). Data from a National Institutes of Health study of 116 OLT recipients (35 HIV/non-HCV recipients and 81 HIV/HCV-coinfected recipients) from 2003 to 2010 (Solid Organ Transplantation in HIV: Multi-Site Study) were analyzed for the pretransplant CKD prevalence [estimated glomerular filtration rate (eGFR) < 60 mL/minute for ≥3 months] and the incidence of CKD up to 3 years posttransplant. Proportional hazards models were performed to assess predictors of posttransplant CKD. A contemporaneous cohort of HCV-monoinfected transplant recipients from the Scientific Registry of Transplant Recipients database was also analyzed. The median age at transplant was 48 years, the median serum creatinine level was 1.1 mg/dL, and the median eGFR was 77 mL/minute. Thirty-four patients were suspected to have pretransplant CKD; 20 of these patients (59%) had posttransplant CKD. Among the 82 patients without pretransplant CKD (26 HIV/non-HCV patients and 56 HIV/HCV-coinfected patients), the incidence of stage 3 CKD 3 years after OLT was 62% (55% of HIV/non-HCV patients and 65% of HIV/HCV-coinfected patients), and the incidence of stage 4/5 CKD was 8% (0% of HIV/non-HCV patients and 12% of HIV/HCV-coinfected patients). In a multivariate analysis, older age [[hazard ratio (HR) = 1.05 per year, P = 0.03] and the CD4 count (HR = 0.90 per 50 cells/μL, P = 0.01) were significant predictors of CKD. HCV coinfection was significantly associated with stage 4/5 CKD (HR = 10.8, P = 0.03) after adjustments for age. The cumulative incidence of stage 4/5 CKD was significantly higher for HIV/HCV-coinfected patients versus HIV/non-HCV transplant recipients and HCV-monoinfected transplant recipients (P = 0.001). In conclusion, CKD occurs frequently in HIV-infected transplant recipients. Predictors of posttransplant CKD include older age and a lower posttransplant CD4 count. HCV coinfection is associated with a higher incidence of stage 4/5 CKD.
丙型肝炎病毒 (HCV) 和人类免疫缺陷病毒 (HIV) 均与慢性肾脏病 (CKD) 相关,这是肝移植术后的主要并发症。本研究旨在评估 HIV/HCV 合并感染受者与 HIV 感染未合并 HCV(HIV/非 HCV 受者)受者在肝移植术后发生 CKD 的预测因素。
对 2003 年至 2010 年间接受肝移植的 116 例患者(35 例 HIV/非 HCV 受者和 81 例 HIV/HCV 合并感染受者)的数据进行了分析,这些患者均来自美国国立卫生研究院的一项研究,即 HIV 肝移植患者的多中心研究。对这些患者的移植前 CKD 患病率[估算肾小球滤过率(eGFR)<60 mL/min 持续 3 个月以上]和移植后 3 年内 CKD 的发生率进行了评估。采用比例风险模型评估了移植后 CKD 的预测因素。同时还分析了来自移植受者科学注册数据库的 HCV 单一感染移植受者的同期队列。
移植时的中位年龄为 48 岁,中位血清肌酐水平为 1.1 mg/dL,中位 eGFR 为 77 mL/min。34 例患者疑似存在移植前 CKD;其中 20 例(59%)在移植后出现 CKD。在 82 例无移植前 CKD 的患者(26 例 HIV/非 HCV 患者和 56 例 HIV/HCV 合并感染患者)中,移植后 3 年时发生 CKD 3 期的比例为 62%(HIV/非 HCV 患者为 55%,HIV/HCV 合并感染患者为 65%),发生 CKD 4/5 期的比例为 8%(HIV/非 HCV 患者为 0%,HIV/HCV 合并感染患者为 12%)。
多变量分析显示,年龄较大([风险比(HR)=每年 1.05,P=0.03])和 CD4 计数较低([HR=每 50 个细胞/μL 0.90,P=0.01])是 CKD 的显著预测因素。调整年龄后,HCV 合并感染与 CKD 4/5 期显著相关([HR=10.8,P=0.03])。与 HIV/非 HCV 移植受者和 HCV 单一感染移植受者相比,HIV/HCV 合并感染患者的 CKD 4/5 期累积发生率显著更高(P=0.001)。
综上所述,HIV 感染的移植受者常发生 CKD。移植后 CKD 的预测因素包括年龄较大和移植后 CD4 计数较低。HCV 合并感染与 CKD 4/5 期发生率较高相关。